Outcome of Extremely Preterm Infants Who Received Systemic Postnatal Corticosteroid for Bronchopulmonary Dysplasia

NCT05055193 · clinicaltrials.gov ↗

COMPLETED

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Bronchopulmonary Dysplasia

Interventions

DRUG: Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome

Sponsor

Hospices Civils de Lyon